1. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW. Prognostic factor in neuroblastoma. Cancer. 1987. 59:1853–1859.
2. Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer. 1980. 46:1896–1901.
Article
3. Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998. 16:1256–1264.
Article
4. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984. 224:1121–1124.
5. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985. 313:1111–1116.
6. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991. 9:581–591.
7. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984. 311:231–235.
Article
8. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, Marsden HB, Misugi K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984. 73:405–416.
Article
9. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999. 86:364–372.
Article
10. Joshi VV, Cantor AB, Brodeur GM, Look AT, Shuster JJ, Altshuler G, Larkin EW, Holbrook CT, Silverman JF, Norris HT. Correlation between morphologic and other prognostic markers of neuroblastoma. A study of histologic grade, DNA index, N-myc gene copy number, and lactic dehydrogenase in patients in the Pediatric Oncology Group. Cancer. 1993. 71:3173–3181.
11. Shuster JJ, McWilliams NB, Castleberry R, Nitschke R, Smith EI, Altshuler G, Kun L, Brodeur G, Joshi V, Vietti T. Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study. Am J Clin Oncol. 1992. 15:295–303.
Article
12. Hann HW, Evans AE, Siegel SE, Wong KY, Sather H, Dalton A, Hammond D, Seeger RC. Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience. Cancer Res. 1985. 45:2843–2848.
13. Zeltzer PM, Marangos PJ, Sather H, Evans A, Siegel S, Wong KY, Dalton A, Seeger RC, Hammond D. Prognostic importance of serum neuron specific enolase in local and widespread neuroblastoma. Prog Clin Biol Res. 1985. 175:319–329.
14. Morris JA, Shochat SJ, Smith EI, Look AT, Brodeur GM, Cantor AB, Castleberry RP. Biological variables in thoracic neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg. 1995. 30:296–302.
Article
15. Suita S, Tajiri T, Sera Y, Takamatsu H, Mizote H, Ohgami H, Kurosaki N, Hara T, Okamura J, Miyazaki S, Sugimoto T, Kawakami K, Tsuneyoshi M, Tasaka H, Yano H, Akiyama H, Ikeda K. The characteristics of mediastinal neuroblastoma. Eur J Pediatr Surg. 2000. 10:353–359.
Article
16. Adams GA, Shochat SJ, Smith EI, Shuster JJ, Joshi VV, Altshuler G, Hayes FA, Nitschke R, McWilliams N, Castleberry RP. Thoracic neuroblastoma: a Pediatric Oncology Group study. J Pediatr Surg. 1993. 28:372–377.
Article
17. Häberle B, Hero B, Berthold F, von Schweinitz D. Characteristics and outcome of thoracic neuroblastoma. Eur J Pediatr Surg. 2002. 12:145–150.
Article
18. Horiuchi A, Muraji T, Tsugawa C, Nishijima E, Satho S, Takamizawa S, Misu H, Mabuchi O, Kanagawa K, Fujita M. Thoracic neuroblastoma: outcome of incomplete resection. Pediatr Surg Int. 2004. 20:714–718.
Article
19. Cruccetti A, Kiely EM, Spitz L, Drake DP, Pritchard J, Pierro A. Pelvic neuroblastoma: low mortality and high morbidity. J Pediatr Surg. 2000. 35:724–728.
Article
20. Moukheiber AK, Nicollas R, Roman S, Coze C, Triglia JM. Primary pediatric neuroblastic tumors of the neck. Int J Pediatr Otorhinolaryngol. 2001. 60:155–161.
Article
21. Abramson SJ, Berdon WE, Ruzal-Shapiro C, Stolar C, Garvin J. Cervical neuroblastoma in eleven infants-a tumor with favorable prognosis. Clinical and radiologic (US, CT, MRI) findings. Pediatr Radiol. 1993. 23:253–257.
22. Berdon WE, Stylianos S, Ruzal-Shapiro C, Hoffer F, Cohen M. Neuroblastoma arising from the organ of Zuckerkandl: an unusual site with a favorable biologic outcome. Pediatr Radiol. 1999. 29:497–502.
Article
23. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castleberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, Kaneto M, Kemshead J, Lampert F, Lee RE, Look AT, Pearson AD, Philip T, Roald B, Sawada T, Seeger RC, Tsuchida Y, Voute PA. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993. 11:1466–1477.
Article
24. Sung KW, Lee SH, Yoo KH, Jung HL, Cho EJ, Koo HH, Lee SK, Kim J, Lim DH, Suh YL, Kim DW. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma. Bone Marrow Transplant. 2007. 40:37–45.
Article
25. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP. Children's Cancer Group. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med. 1999. 341:1165–1173.
Article
26. Ladenstein R, Philip T, Lasset C, Hartmann O, Garaventa A, Pinkerton R, Michon J, Pritchard J, Klingebiel T, Kremens B, Pearson A, Coze C, Paolucci P, Frappaz D, Gadner H, Chauvin F. Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry. J Clin Oncol. 1998. 16:953–965.
Article
27. Berthold F, Boos J, Burdach S, Erttmann R, Henze G, Hermann J, Klingebiel T, Kremens B, Schilling FH, Schrappe M, Simon T, Hero B. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomized controlled trial. Lancet Oncol. 2005. 6:649–658.
28. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cellsupported transplantation: long-term survival update. J Clin Oncol. 2006. 24:2891–2896.
Article
29. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW, Cohn SL. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002. 20:2284–2292.
Article